FDA Purple Book · Reference family
erenumab-aooe (Aimovig)
erenumab-aooe is an FDA-licensed reference biologic from Amgen Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2018
Reference approved
Reference product
351(a)BLA 761077
Aimovig erenumab-aooe
Amgen Inc.
- Approved
- May 17, 2018
- Marketing
- Disc
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for erenumab-aooe, in chronological order.
Reference approval
Approval date of the reference erenumab-aooe product.
8 yr 2 mo ago
Frequently asked questions
Are there biosimilars approved for erenumab-aooe (Aimovig)?
No 351(k) biosimilars or interchangeable biosimilars referencing erenumab-aooe are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.